Objective: To determine the polymorphisms in the 3 0 untranslated region (3 0 UTR) of the G6PD gene and analyze the specific SNPs or haplotypes that may affect messenger RNA (mRNA) secondary structure by in silico analysis.
Glucose-6-phosphate dehydrogenase is the key enzyme in the pentose phosphate pathway (PPP) and provides reductive potential in the form of nicotinamide adenine phosphate (NADPH), which is required for protection against oxidative processes.
1 Because erythrocytes do not contain mitochondria, PPP is their only source of NADPH. Therefore, G6PD-deficient erythrocytes are more susceptible to destruction by oxidative stress than normal erythrocytes due to their lower NADPH levels. 2 Most G6PD-deficient individuals are asymptomatic but they are susceptible to acute hemolysis after exposure to oxidant chemicals or drugs. 3 G6PD deficiency, the most commonly inherited enzymopathic disorder, is carried by potentially more than 400,000,000 individuals worldwide. 4, 5 G6PD deficiency is caused by 1 or more variants in the G6PD gene (MIM:305900) on chromosome X. These variants lead to functional variants of the protein, resulting in different severities and patterns of clinical manifestation among individuals with G6PD deficiency.
At present, approximately 400 biochemical and more than 190 molecular variants of the G6PD enzyme have been reported in various populations, nearly all of which are single-base substitutions that cause amino-acid substitutions. 6 The World Health Organization (WHO)
classifies the G6PD variants into the following 5 classes according to the level of residual enzyme activity and clinical manifestations: class I, severe enzyme deficiency associated with chronic nonspherocytic hemolytic anemia (CNSHA); class II, severely deficient (less than 10% residual activity) Abbreviations G6PD, glucose-6-phosphate dehydrogenase; PPP, pentose phosphate pathway; NADPH, nicotinamide adenine phosphate; WHO, World Health Organization; CNSHA, chronic nonspherocytic hemolytic anemia; AHA, acute hemolytic anemia; SNPs, single-nucleotide polymorphisms; miRNAs, microRNAs; 3 0 UTR, 3 0 untranslated region; ICH-GCP, International Conference on Harmonization-Good Clinical Practice; CPDA, citrate phosphate dextrose adenine; PCRs, polymerase chain reactions; dNTP, deoxynucleoside triphosphates; Ta, annealing temperature; gHb, gram of hemoglobin; Dassociated with acute hemolytic anemia (AHA); class III, moderately deficient (10% to 60% residual activity); class IV, normal activity (60% to 150%); and class V, increased activity. 7 By contrast, only approximately 90 molecular defects have been identified as being responsible for such variants, demonstrating less genetic heterogeneity than would be expected based on the biochemical data.
Although comprehensive studies have identified the molecular basis of G6PD deficiency worldwide, the existing G6PD genetic variation has been unclear in explaining the expression of G6PD deficiency. The use of G6PD variants only as population markers is limited because few haplotypes have been identified, 8 which causes misdiagnosis of G6PD deficiency at the phenotype level. Thus, the information regarding polymorphic G6PD variants and single-nucleotide polymorphisms (SNPs) is necessary for reconstructing the evolutionary history of the G6PD gene. Further investigations should study other possible mechanisms to explain gene-expression control. At present, one interesting mechanism is post-transcriptional control by microRNAs (miRNAs). miRNAs specifically bind the 3 0 untranslated region (3 0 UTR) of target genes. 9 Therefore, we hypothesize that 3 0 UTR genetic variations may affect mRNA secondary structure, leading to decreased G6PD enzyme expression. This study aimed to determine the polymorphisms in the 3 0 UTR of the G6PD gene in healthy subjects living in Thailand (ethnicities unknown) individuals and analyze the specific SNP(s) or haplotypes that may affect the mRNA secondary structure of the G6PD gene.
Materials and Methods

Specimen Collection and DNA Extraction
We recruited a total of 107 apparently healthy volunteers, aged 19 years to 49 years, with unknown G6PD deficiency status. All subjects had no concurrent infection and no history of hematologic disorder; none had been hospitalized for 3 months or longer. 
Identification of G6PD Variants
We assessed all variants in the 3 0 UTR and exons 6, 9, 11, 12, and 13 of the G6PD gene, which cover common variants in Southeast Asia countries, especially Thailand, 5,10-15 and newly identified G6PD variants in Thailand, such as G6PD Bangkok Noi, which are located in exon 12 and 13. 16 Next, DNA templates were amplified using the KAPA2G Robust HotStart DNA Polymerase Kit (Kapa Biosystems) according to the manufacturer-provided instructions.
Polymerase chain reactions (PCRs) were composed of Master Mix (containing nuclease-free water), 5Â KAPA2G buffer, 25 mM MgCl 2 , 10 mM of deoxynucleoside triphosphates (dNTP) mix, 10 mM of specific primers, and 5 U/mL KAPA2G Robust HotStart DNA Polymerase. PCR conditions started with initial denaturation at 95 C for 3 minutes, followed by 40 cycles of 95 C for 30 seconds, annealing temperature (Ta) for 45 seconds, and 72 C for 30 seconds, with a final extension at 72 C for 7 minutes. PCR was carried out using an Eppendorf Mastercycler ep Gradient S thermal cycler (Eppendorf AG). Target PCR products were detected by 2% agarose gel electrophoresis.
Next, the PCR product was purified using a FavorPrep GEL/ PCR Purification Kit (Favorgen Biotech Corp), followed by unidirectional direct sequencing using an ABI 3730xl Genetic Analyzer (Applied Biosystems Inc.). Finally, the chromatograms of the DNA sequences were analyzed using Sequence Scanner version 1.0 software and Biological Sequence Alignment Editor (BioEdit) by comparing them with the G6PD reference sequence (retrieved sequence from the UCSC Genome Browser website: http://genome.ucsc.edu/).
Measurement of G6PD Enzyme Activity
We stored CPDA blood specimens at 4 C and used them We conducted haplotype association testing based on the permutation procedure, using Haploview software. Permutation P values were calculated for single mutation markers and haplotypes from 100,000 permutations. A P value of less than .05 was considered statistically significant. G*Power software, version 3.0.10, was used to calculate the sample size. 24 We calculated the sample size for at least 44 individuals to analyze haplotype and G6PD enzyme activity via v 2 testing using Haploview software, version 4.2, based on the following value: a power of 0.80 and an alpha level of 0.05. On the assumption of 5% to 10% nonevaluable population, the acceptable sample-size range was at least 47 to 49 enrolled individuals.
Results
Genetic Variation in the G6PD Gene
After sequencing using 4 primer pairs for exons 6, 9, 11, 12, 13 and the 3 0 UTR, including intron boundaries, PCR product sizes ranged from 553 bp to 848 bp ( Table 1) . In this study, we found 12 variants, 11 of which were previously reported and 1 of which was a new variant (c.*99A > G). (c.*99A > G); however, there were fewer of these than of the combinations ( Table 3) .
LD Structure and Haplotype Analysis
A total of 13 G6PD variants (8 in exons, 2 in introns, and 3 in 3 0 UTRs) of the total samples were analyzed using
Haploview software, version 4.2. All G6PD variants were accepted for Hardy-Weinberg equilibrium (HW P> .05) ( Table 2 ). The results of the linkage disequilibrium pattern revealed that there was 1 haplotype block in the G6PD gene in this study. This haplotype block started from exon Figure 2A .
Next, we identified the variants that had minimum minor allele frequency (MAF) and Hardy-Weinberg equilibrium (HW) P-value cutoff of greater than .05 and percentage of genotype greater than 80%. The results revealed that the haplotype block remained unchanged, including the same variants in the block ( Figure 2B ). Significant linkage disequilibrium was detected in 
. In this study, the G6PD gene showed 4 haplotypes associated with those variants, namely, haplotype G1 (GCTA), haplotype G2 (GTCG), haplotype G3 (ATCG), and haplotype G4 (GCCG). The frequencies of haplotypes G1, G2, G3, and G4 were 69.9%, 17.1%, 12.4%, and 0.5%, respectively ( Figure 2C ).
Next, haplotype analysis was demonstrated with sex discrimination in male and female groups using Haploview software, version 4.2. For the male group, 1 block of haplotypes was different from the whole population. Two haplotypes, namely, haplotype GM1 (TCG) and haplotype GM2 (CTA), were associated with 3 G6PD variants, silent variant-2 (c.1311C > T), IVS-11 (n.þ93T > C), and 3 0 UTR (c.*357A > G), as a haplotype for the whole population except for the Viangchan variant (c.871G > A) ( Figure 3 , part a). The percentages of haplotype GM1 (TCG) and haplotype GM2 (CTA) were 52.4% and 47.6%, respectively ( Figure 3B ). 
No mutation
and c.*357A>G
Combinations of 3 c.1311C>T, n.þ93T>C, and c.*357A>G
c.1024C>T, c.1388G>A, and c.*548C>T
Combinations of 4 c.871G>A, c.1311C>T, n.þ93T>C, and c.*357A>G
c.1311C>T, n.þ93T>C, c.*357A>G, and c.*548C>T
Combinations of 5 c.871G>A, c.1311C>T, n.þ93T>C, c.*357A>G, and n.þ50G>A
c.871G>A, c.1311C>T, n.þ93T>C, c.*357A>G, and c.487G>A
c.871G>A, c.1311C>T, n.þ93T>C, c.*357A>G, and c.1360C>T
population, there were different percentages of haplotypes. The 4 haplotypes of the female group were haplotype GF1 (GCTA), 72.7%; haplotype GF2 (GTCG), 14.0%; haplotype GF3 (ATCG), 12.8%; and haplotype GF4 (GCCG), 0.6% ( Figures 4A, 4B , and 4C).
Effect of G6PD Polymorphism on Enzyme Activity
To evaluate the effect of the single variants and the variants combinations in the G6PD gene, we analyzed the expression of the G6PD enzyme as a measurement of G6PD enzyme activity. We divided the specimens by G6PD genetic variation 
G6PD Haplotype-Phenotype Correlation of the G6PD Gene
We further analyzed the association of G6PD variants with G6PD deficiency via case/control studies using Haploview software, version 4.2. We divided individuals into 2 groups according to the level of residual enzyme activity, including residual enzyme activity greater and less than 60% of normal activity. For the association test of a single G6PD variant, only the Viangchan variant (c.871G > A), showed statistically significant differences between the G6PD-deficient group and the normal group in total specimens (permutation P value ¼ 3.0000E-5), males (permutation P value ¼ .01) and females (permutation P value ¼ .001) ( Table 4 ). In the total specimens (N ¼ 107), haplotype associations were significantly different (P <.05). Two haplotypes (haplotype G2 and haplotype G3) were significantly different between the G6PD deficient and normal groups (P ¼ .048 and P ¼ 9.7908E-7, respectively) ( Table 5) .
Next, we corrected the P value using permutation testing via Haploview software for single markers and haplotypes in blocks (100,000s of permutations). Only haplotype G3 (ATCG) was still significant (P <.001). However, haplotype G2 (GTCG) did not show significant differences after the permutation test. Haplotype G3 revealed an odds ratio (OR) of 7.90, and the 95% confidence interval (CI) range was 3.15 to 19.81 (Table 5) .
Regarding the results of association testing of the male population, all haplotypes (GM1: TCG and GM2: CTA) did not show significant differences ( Table 5 ). In the female population, association testing revealed that only haplotype G3 (ATCG) was significantly different in the G6PD-deficient group and the normal group (permutation P value ¼ .001).
The odds ratio and the 95% CI range of the Viangchan variant in females were 6.14 and 2.36 to 15.96, respectively ( Table 5) . The Viangchan variant (in total specimens, male and female groups) and haplotype G3 (in total specimens and female group) were more frequently found in individuals with severe and moderate G6PD deficient activity than in individuals with normal G6PD activity ( Table 4 and Table 5 ). Therefore, the Viangchan variant and haplotype G3 are significantly associated with the severity of G6PD deficiency.
Prediction of the Effect of G6PD VariantsAssociated Haplotype on the Secondary Structure of G6PD mRNA and Protein and MicroRNA Binding
These results showed significant differences in G6PD enzyme expression in some variants and haplotypes. The Viangchan variant causes a missense mutation that changes an amino acid, thereby decreasing G6PD enzyme activity.
To explain the role of the haplotype (which consists of 
Figure 5
Correlation between G6PD enzyme expression and genetic variation of the G6PD gene (MIM:305900); significant difference indicated by * (P value <.05) and ** (P value <.001), compared with none of variants and 3 combination. Males and females are indicated by grey triangles and black circles, respectively. missense and silent mutations) in G6PD enzyme expression, we evaluated the mRNA secondary structure. The haplotype G1 (GCTA) had wild-type alleles of G6PD mRNA in all 4 variants. The secondary structure of haplotype G1 was shown; the minimum free energy was À918.8 kcal mol À1 ( Figure 6A ). Next, we analyzed the secondary structure of the haplotype G3 (ATCG) that showed significant differences between G6PD deficient and normal groups after the permutation test. The 3 variants of the haplotype were the Viangchan variant, silent variant-2, and the c.*357A > G variant in positions 984, 1424, and 2018, respectively, of the mRNA sequence. The haplotype G3 contained the total
Figure 6
The secondary structure and the Gibbs free energy of haplotypes. A, Haplotype G1 (GCTA): À918.8 kcal/mol À1 . B, Haplotype G3 (ATCG):
À921.5 kcal/mol À1 . This haplotype G3 showed significant change in G6PD mRNA secondary structure. to À 921.5 kcal mol À1 ( Figure 6B) . The c.*357A > G variants at position 2018 might affect the G6PD mRNA that showed secondary structure changes with this haplotype ( Figure 6B ).
Via in silico analysis, we predicted the effect of G6PD variants associated with G6PD mRNA secondary structure changes, including the Viangchan variant (c.871G > A), silent variants-2 (c.1311C > T), and 3 0 UTR (c.*357A > G). For the Viangchan variant (c.871G > A), the risk level was high, and the risk type was missense (nonconservative change), as determined using VarioWatch software ( Figure 7) . Then, deriving a score of 1.000 using PolyPhen-2 software, we predicted this missense mutation to be probably damaging. Moreover, using PROVEAN software, the Viangchan variant also was predicted to be deleterious, with PROVEAN score of À2.583, which indicates a partially functional protein. The silent variants-2 (c.1311C > T) variant was predicted to be very low risk because it did not have nonsynonymous SNPs and did not cause exonic splicing enhancer (ESE) or exonic splicing silencer (ESS) motif diminishment. Variation in the untranslated region (c.*357A > G) was not analyzed using VarioWatch (Figure 7 ).
RegRNA software, version 2.0, predicted that 3 0 UTR (c.*357A > G) SNPs affected the binding of 2 miRNAs, namely, hsa-miR-3124-3p at position 2011-2032 of G6PD mRNA (created) and hsa-miR-4646-3p at position 1999-2020 of G6PD mRNA (abolished) (summarized in Table 6 ). We compared changes in the G6PD mRNA secondary structure of haplotype G3 with the haplotype analysis; haplotype G3 showed reduced G6PD enzyme expression and high OR in the severe and moderate group, compared with those of the normal-G6PD-activity group. Moreover, the bioinformatics software predicted that haplotype G3 resulted in aberrant functional protein and microRNA binding.
Discussion
Genetic analysis of the G6PD gene in the healthy subjects living in Thailand (ethnicities unknown) population in this study revealed that G6PD genetic variations were mostly identifiable in combination patterns. The most common combinations were 3 combinations (c.1311C > T, n.þ93T > C, and c.*357A > G), followed by 4 combinations (c.871G > A, c.1311C > T, n.þ93T > C, and c.*357A > G), at 26.2% and 18.7%, respectively, of the total combinations. In this study, more than half of the total individuals (51.4%) had G6PD genetic variation combinations (2, 3, 4, and 5 combinations), compared with G6PD single genetic variations (9.3%). These results conflict with the results of previous studies. The previous results usually showed single G6PD genetic variation and did not commonly reveal G6PD gene combinations in healthy subjects living in Thailand (ethnicities unknown) populations. 5, 11, 25 The discrepancy between these results may be associated with technical differences in the genetic variant analyses. Previous studies of G6PD genetic analysis mostly used PCR-restriction fragment-length polymorphisms (RFLPs). 5, 11, 25, 26 By contrast, in this study, we analyzed G6PD gene variation using DNA sequencing.
Although we identified mostly single variants in the G6PD gene, combination variations have been reported in other populations. In 2013, Amini and Ismail 27 reported that G6PD
c.1311C > T/n.þ93T > C/c.*357A > G was the predominant variant (approximately 83.3%) in the Negrito group of Malaysia, a highly homogenous subpopulation. We also found these 3 variants in the healthy subjects living in Thailand (ethnicities unknown) population, similar to the Negrito group, in different prevalences. Combinations of 4 variants usually included Viangchan variant-combined combinations of 3 variants (c.871G > A, c.1311C > T, n.þ93T > C, and c.*357A > G). One explanation is that the Viangchan variant is the common G6PD variant in the healthy subjects living in Thailand (ethnicities unknown) population. 5 Thus, we detected combination-variant differences in the healthy subjects living in Thailand (ethnicities unknown) population, compared with the Negrito group.
Next, we assessed the effect of G6PD genetic variation in combination patterns, including single variants, using G6PD enzyme activity. Most people who had G6PD variants had less G6PD activity than did the normal group (no variants), except for some individuals who had G6PD variation in silent variants. Groups with lower enzyme expression consisted of single variants and 2, 3, 4, and 5 combinations. However, some people with 2, 3, or 4 combinations showed normal G6PD activity because all variants that existed in these 3 types of combinations were silent variants that do not change the amino acid. In contrast, single nonsynonymous variants showed low G6PD activity, although we only observed
Figure 7
Prediction of the effect of G6PD variants associated with haplotype G3 to protein (G6PD enzyme). Haplotype G3 that consisted of Viangchan variant (c.871G > A), silent variantsÀ2 (c.1311C > T), and 3 0 untranslated region (3 0 UTR) (c.*357A > G) was predicted using the VarioWatch program. for this finding is random X-chromosome inactivation. 28, 29 Other pathogenic variants that reduce G6PD expression may exist in uncovered regions of our sequencing strategy, affecting G6PD enzyme expression. Nevertheless, the sequenced region covers the common variants in Southeast Asian countries, especially Thailand. 5,10-16 However, we believe that G6PD may associate with other factors, such as haplotype or mRNA secondary structure of the G6PD gene.
Haplotypes of the G6PD gene were analyzed using Haploview software, version 4.2. There were 4 variants (1 missense variant and 3 silent variants) associated with only 1 block of haplotypes on the G6PD gene in the total population and the female group. These variants consisted of the Viangchan variant (c.871G > A, rs137852327), silent variants-2 (c.1311C > T, rs2230037), IVS11 (n.þ93T > C, rs2071429), and 3 0 UTR (c.*357A > G, rs1050757). There were 4 haplotypes in different degrees of prevalence ( Figure 2C and Figure 4C ). In contrast, the haplotype block of the male group was different from the total sample and female groups; it might be affected by sample number differences. Difference types and haplotype prevalence depend on countries and population because G6PD variants and haplotypes are specific to regions and nationalities. 8, [30] [31] [32] [33] [34] [35] In the present study, the haplotype GCTA, which was commonly encountered, had a frequency in the total population of approximately 70.0% and in females of approximately 72.7%; this haplotype consisted of all wild-type alleles in each variants.
Haplotype GCTA was also found in the group with normal G6PD activity (>60% of normal activity) more frequently than in the group with G6PD deficiency (<60% of normal activity), including haplotypes GTCG and GCCG. We observed haplotype ATCG in the G6PD-deficient group more frequently than in the group with normal G6PD values of the total population and female groups. We were surprised to discover that this haplotype ATCG was significantly different after the 100,000-permutations test (P <.001) and consisted of all mutant alleles in 4 variants. Moreover, the Viangchan variant was the only single variant with a statistically significant difference (P <.001). The results of both of these tests revealed high equal ORs in the total sample and female groups. Thus, it is possible that the significant haplotype G3 (ATCG) might be directly affected by the Viangchan variant (a missense mutation). However, in this study, we observed no single Viangchan variants. When we observed the Viangchan variant, it was always present with the 3 G6PD variants (c.1311C > T, n.þ93T > C, and c.*357A > G) that associated with haplotype G3. Therefore, the 3 G6PD variants associated with haplotype G3 might be an enhancing factor that affects G6PD enzyme expression, unlike the single Viangchan variant. Together, these results provide genetic evidence that not only single genetic variations but also the haplotype of the G6PD gene influence G6PD enzyme expression, especially in females.
We analyzed the role of haplotypes, which showed significant differences between the normal-G6PD and G6PD-deficient groups, was analyzed by prediction of G6PD mRNA secondary structure. Using in silico analysis, significant changes were predicted with haplotype ATCG. The first position of this haplotype was the mutant allele of the Viangchan variant, which exists in an exon. Previous reports 36 indicates that most of the variants in exonic regions (causes of amino-acid substitution) affect the alteration of mRNA structure. Moreover, the 3 0 UTR of the human G6PD are significant for the stability of the mRNA though mRNA secondary structure changes. [37] [38] [39] Further, using RegRNA software, version 2.0, we predicted that the 3 0 UTR (c.*357A > G) variants would affect microRNA binding (hsa-miR-4646-3p and hsa-miR-3124-3). Previous evidence 40 demonstrates that synonymous variants in coding regions lead to alterations in mRNA folding structure, as observed with human alanyl transfer RNA (tRNA) synthetase and human replication protein A mRNA. In addition, another report 41 explains that combinations of silent variants may influence functional effects significantly differently than single variants. An example of this phenomenon is the mRNA stability change resulting from synonymous variants in the human dopamine receptor D2. This finding is consistent with those of previous reports that the c.871G > A, c.1311C > T, n.þ93T > C, and c.*357A > G variants combinations that comprised haplotype ATCG lead to decreased G6PD enzyme activity, which was derived via predictions made using bioinformatics tools (VarioWatch, Polyphen-2, and PROVEAN software).
Conclusions
The results of the present study showed the association of 3 0 UTR variation with G6PD deficiency and revealed 1 new variant (c.*99A > G). This is the first report on G6PD gene haplotypes in the healthy subjects living in Thailand (ethnicities unknown) population, to our knowledge. Moreover, the haplotype ATCG was associated with reduced G6PD enzyme expression using Haploview software. As determined via in silico analysis, this haplotype affected the G6PD mRNA secondary structure changes and microRNA binding that were predicted by the CLC Main Workbench 6.9 and RegRNA 2.0 programs. However, further experimental studies should be performed to confirm the truly affected haplotype and role(s) of the G6PD mRNA secondary structure to explain the severity of G6PD deficiency and contribute to more robust diagnosis for individuals with G6PD deficiency. LM
